Ho K Y, Samarasinghe D A, Nicholson G I, Lane M R
Gastroenterology Department, Westmead Centre, Sydney, New South Wales, Australia.
J Gastroenterol Hepatol. 1995 Jan-Feb;10(1):56-9. doi: 10.1111/j.1440-1746.1995.tb01048.x.
To assess the degree of palliation, the associated morbidity and mortality and to compare our results with other published series, we reviewed our use of the Atkinson prosthesis in 100 consecutive patients for the palliation of unresectable oesophageal carcinoma. The group had a mean age of 71.2 +/- 2.3 years. All prostheses were placed by the pulsion method. Intubation was successful in 91%. Improvement in swallowing was seen in 82.1%. Major early procedure-related morbidity was high at 23% with 11 perforations (11%). Procedure-related mortality was 12%. Those aged 70 years or more had a 34.5% risk of morbidity and 15.5% risk of dying from the procedure. Late procedure-related complications requiring further endoscopic procedures occurred in 27%. Our 7 day mortality was 14.7% (14 patients) and 31 patients (32.6%) had died within 30 days, usually from the disease itself. Those surviving the procedure (> 7 days) had a mean survival of 105 (range 9-735) days. We obtained acceptable palliation but with a significant morbidity and mortality. Endoscopic intubation remains a useful palliative treatment for patients with unresectable carcinoma of the oesophagus and cardia.
为了评估缓解程度、相关的发病率和死亡率,并将我们的结果与其他已发表的系列研究进行比较,我们回顾了连续100例使用阿特金森假体治疗不可切除食管癌的患者情况。该组患者的平均年龄为71.2±2.3岁。所有假体均采用推送法置入。插管成功率为91%。吞咽改善率为82.1%。早期主要的手术相关发病率较高,为23%,其中11例穿孔(11%)。手术相关死亡率为12%。70岁及以上患者手术相关发病风险为34.5%,死亡风险为15.5%。需要进一步内镜治疗的晚期手术相关并发症发生率为27%。我们的7天死亡率为14.7%(14例患者),31例患者(32.6%)在30天内死亡,通常死于疾病本身。手术存活者(>7天)的平均生存期为105天(范围9 - 735天)。我们获得了可接受的缓解效果,但发病率和死亡率较高。内镜插管仍然是治疗不可切除食管癌和贲门癌患者的一种有效的姑息治疗方法。